SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

PMCB RSS Feed
Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Peacefulwendy, $Pistol Pete$, thenewmixer, fraum, concordia
Search This Board: 
Last Post: 9/22/2017 12:09:04 AM - Followers: 785 - Board type: Free - Posts Today: 1

Welcome to PharmaCyte BioTech
An OTCQB Company

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its "cancer" killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one-third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver (where ifosfamide is normally activated) and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.






 


 





FDA Grants Orphan Drug Designation to Pharmacyte Biotech for Pancreatic Cancer Treatment



European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte’s subsidiary,
PharmaCyte Biotech Europe Limited, for PharmaCyte’s pancreatic cancer treatment

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2009/11/human_orphan_000395.jsp&mid=WC0b01ac058001d12b

 Company Address
   
PharmaCyte Biotech, Inc.

23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92652
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com
http://pharmacyte.com/
 

Market Value:
$122,386,272 a/o Dec 19, 2016

Shares Outstanding:
848,904,665 a/o Aug 29, 2016

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

Float:
817,204,665 a/o Aug 29, 2016


For more updated information please visit: 


http://www.otcmarkets.com/stock/PMCB/profile


Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations


Stonegate Capital Inc.
8201 Preston Road
Suite 325
Dallas, TX 75225
United States

 

   All News Releases: 

http://www.pharmacytebiotech.com/news/

 


What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.


http://austrianova.com/products/ 



Management Team:

Kenneth L. Waggoner, Chief Executive Officer and President
 

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director


Carlos A. Trujillo – Chief Financial Officer and Director


Walter H. Gunzburg – Chief Scientific Officer


Dr. Matthias Lohr as Chairman of Scientific Advisory Board


Thomas Liquard - Chairman of the Audit Committe

  Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development

Dr. Manuel Hidalgo, Scientific Advisory Board

 


 

 

 


***DISCLAIMER***
-  The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
-  We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
-  There are no guarantees when buying or selling any security.





 
 


                                   

 
 
SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
PMCB
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB News: Securities Registration Statement (simplified Form) (s-3) 09/13/2017 09:26:54 AM
PMCB News: Quarterly Report (10-q) 09/13/2017 06:06:08 AM
PMCB News: Current Report Filing (8-k) 09/06/2017 08:00:54 AM
PMCB News: Annual Report (10-k) 07/27/2017 05:24:39 PM
PMCB News: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 07/26/2017 09:00:00 AM
PostSubject
#75292  Sticky Note $PMCB PharmaCyte is preparing for a clinical trial $Pistol Pete$ 09/19/17 09:36:07 PM
#62231  Sticky Note in full/ #2/ 01-28-2017/ Keeping an Eye on mick 01/28/17 07:35:33 PM
#52881  Sticky Note Here is a very nice list of accomplishments... Peacefulwendy 09/28/16 11:17:44 AM
#75384   He is when he's not in Alaska snowcrab75 09/22/17 12:09:04 AM
#75383   Austrianova is really Jensen in disguise! Shhh don’t frosr6 09/21/17 11:42:28 PM
#75382   Are you really shorting a penny stock ? Hahahahaha Agreenfo 09/21/17 11:25:52 PM
#75381   That was the news. They partnered with Austrianova concordia 09/21/17 10:30:35 PM
#75380   Where is the GD NEWS?? Uboat 09/21/17 09:05:08 PM
#75378   $PMCB Dr. Matthias Löhr, Chairman of PharmaCyte's Medical $Pistol Pete$ 09/21/17 03:52:26 PM
#75376   Isn't placement in the body improved as well Mens et Manus 09/21/17 12:58:51 PM
#75375   In the Phase 1/2 clinical trial only a concordia 09/21/17 12:57:29 PM
#75374   Every time PMCB having an all out attack ferenc 09/21/17 12:39:42 PM
#75373   And this time they can keep giving doses 1234jklm 09/21/17 11:56:05 AM
#75372   ..First things first, let's keep in mind PharmaCyte's Triple9 09/21/17 11:31:20 AM
#75371   PharmaCyte Biotech on Schedule for 2016 Cancer Clinical concordia 09/21/17 11:31:02 AM
#75370   Remember when we were waiting in Austrianova to frosr6 09/21/17 11:27:03 AM
#75369   Our partners at Eurofins Lancaster Laboratories are developing Triple9 09/21/17 11:23:07 AM
#75368   They have done nothing with CIAB. Formula same frosr6 09/21/17 11:22:57 AM
#75367   What's that worth 100 bucks? "pmcb owns 14.5% frosr6 09/21/17 11:21:57 AM
#75365   What am I missing here, because this is Triple9 09/21/17 09:56:02 AM
#75364   ok its not hard .....as you have said thenewmixer 09/21/17 09:32:31 AM
#75363   Austrianova is in Singapore and Thailand. I'm Triple9 09/21/17 09:31:31 AM
#75362   $PMCB The Chairman of Austrianova was one of $Pistol Pete$ 09/21/17 09:28:15 AM
#75361   There is a big difference between trading and concordia 09/21/17 09:25:57 AM
#75360   That's about the going rate for market research Triple9 09/21/17 09:24:44 AM
#75359   I guess it wasn't abundantly clear but I Triple9 09/21/17 09:20:04 AM
#75358   Austrianova greatly improved CiaB in 2015 and new Triple9 09/21/17 09:13:44 AM
#75356   Without posting much detail....there are 3 things to efood125 09/21/17 08:31:35 AM
#75351   Hmmmmm....Austrianova Chairman Gunzburg in China....what a coincidence. efood125 09/21/17 07:30:13 AM
#75344   Scam site BEWARE $4,450-$6,250 for a report! Global frosr6 09/21/17 03:37:51 AM
#75343   $PMCB Pancreatic cancer Market Clinical Trials Review, H $Pistol Pete$ 09/21/17 02:29:23 AM
#75342   Notice the links to Nasdaq website are the frosr6 09/21/17 02:14:33 AM
#75341   Again WRONG but luckily I'm here to offer frosr6 09/21/17 02:07:35 AM
#75340   I wonder if the fact Stock market media frosr6 09/21/17 01:44:31 AM
#75339   $PMCB Gold Standard Cell-In-The-Box Technology: Pharmacy $Pistol Pete$ 09/21/17 01:41:27 AM
#75338   WRONG AGAIN. Why tell us there is frosr6 09/21/17 01:29:21 AM
#75337   $PMCB 6 Institutional Holders (1,245,919 Total Shares He $Pistol Pete$ 09/20/17 10:33:49 PM
#75336   Pmcb has no patents for CIAB anymore. CIAB frosr6 09/20/17 09:08:36 PM
#75334   For 2 grand you could open a margin frosr6 09/20/17 08:57:51 PM
#75333   With 1.5m average volume good luck with trying frosr6 09/20/17 08:52:51 PM
#75332   My thoughts on the matter as well. Good Brian903 09/20/17 08:38:27 PM
#75331   Lots of accomplished in my eyes and I $Pistol Pete$ 09/20/17 07:10:45 PM
#75330   I got more money going to my brokerage, GELRaZ 09/20/17 06:46:48 PM
#75329   People have been saying "it's coming" over and SirCharChar 09/20/17 06:45:24 PM
#75328   great post you should sticky in tells all thenewmixer 09/20/17 06:29:34 PM
#75327   $PMCB Dr. Matthias Löhr 2017 ASCO Interview PMCB [ $Pistol Pete$ 09/20/17 05:40:54 PM
#75326   You can't ignore past failures and expect new concordia 09/20/17 05:09:27 PM
#75325   They are coming ;-) Go $PMCB $Pistol Pete$ 09/20/17 05:01:27 PM
#75324   this is like waiting for Christmas just with stanchjojoina 09/20/17 04:40:02 PM
#75323   Lots of buying pressure happen at the last $Pistol Pete$ 09/20/17 04:09:18 PM
#75322   Upcoming trial is what count the most. This $Pistol Pete$ 09/20/17 03:29:38 PM
#75321   These are the only trials ever conducted with concordia 09/20/17 03:28:08 PM
#75320   I was wondering that too but apparently day Triple9 09/20/17 02:05:02 PM
PostSubject